NetNoggin® releases exploratory analysis “Alzheimer’s Recent Drug Failures”

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

FREDERICK, Md., Oct. 2, 2019 /PRNewswire/ — An exploratory study, conducted by NetNoggin®, revealed that among those impacted by Alzheimer’s, hope of finding a cure is deflating due to recent Alzheimer’s clinical trial failures in the past few years:

Inspired by the consumer. (PRNewsfoto/NetNoggin)Inspired by the consumer. (PRNewsfoto/NetNoggin)

  • January 2018 – Pfizer pulled out of the Alzheimer’s space
  • January 2018 – Eli Lilly/AstraZeneca abandoned lanabecestat
  • February 2018 – Merck abandoned verubecestat
  • January 2019 – Roche stopped crenezumab trials
  • March 2019 – Biogen/Eisai discontinued aducanumab trials
  • July 2019 – Amgen/Novartis halted trials for CNP520
  • September 2019 – Neurotrope failed to meet Bryostatin-1 primary endpoints

In fact, the last successful Alzheimer’s drug approval was in 2014 for NAMZARIC. Manufacturers acknowledge current drugs for Alzheimer’s only treat symptoms as the disease continues to progress.

In response to news regarding failed clinical trials, caregivers are posting responses claiming this news makes them “depressed’ and “pessimistic”.  Yet, researchers and foundations remain hopeful despite the failures. For example, George Vradenburg, the head of USAgainstAlzheimers, posted on Twitter, “Let’s keep failing … until we succeed … [help] us all to remain hopeful in the fight against #Alz.”

Results from NetNoggin‘s analysis also show growing concern that the amyloid hypothesis may be the wrong target and other mechanisms should be considered. The community suggests the following next steps:

  • Continue to research amyloids as a target (learning from failures)
  • Consider prevention as the best way to treat Alzheimer’s
  • Further research BACE inhibitors with lower doses and at earlier disease stages
  • Explore the failed cancer drug, farnesyltransferase inhibitors, for Alzheimer’s
  • Consider personalizing treatment (genetic research on CHRFAM7A genotype)
  • Continue to research other mechanisms and pathways of Alzheimer’s

Visit https://netnoggin.net/exploratory-analysis to request the full exploratory analysis.

About NetNoggin®
NetNoggin®, a subsidiary of Conger Consulting, LLC, is a premier market research agency that specializes in pharmaceutical marketing. NetNoggin® utilizes netnography to analyze and provide context to Big Data. By leveraging 30+ years of experience, their proprietary process derives strategic consulting insights from Big Data to inform Foundational Marketing Tools (FMTs), strategies, and tactics. NetNoggin® has expertise in market research; commercial, market, and clinical development; and communications to provide reliable research, presentations, and workshops.

NetNoggin® Media Relations
If you would like more information on this topic, please contact Megan Newcomer.
E-mail: megan.newcomer@netnoggin.net

View original content to download multimedia:http://www.prnewswire.com/news-releases/netnoggin-releases-exploratory-analysis-alzheimers-recent-drug-failures-300930053.html

SOURCE NetNoggin

Staff

Recent Posts

TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), a company working to improve outcomes for…

2 hours ago

As Dangerous US Heat Wave Intensifies, AccuWeather Urges Public to Rely on Science-Backed RealFeel® Temperature for Accurate Danger Index

AccuWeather's RealFeel® Temperature is the only authentic formula-based metric—unlike 'Feels Like,' which lacks scientific credibility.Request…

2 hours ago

New Data Signals IVD Growth in a Shifting Market Amid Tariff Uncertainty

Kalorama Identifies Point-of-Care Testing Momentum and Strategic Blind Spots in Latest Diagnostic Trends Analysis ARLINGTON,…

2 hours ago

Medmovie Hx Heart App Launch Elevates Health Literacy and Empowers Shared Decision Making for Cardiovascular Care

Digital tool equips healthcare providers with trusted visual content to simplify complex heart information at…

2 hours ago

Premera Blue Cross Blue Shield of Alaska Announces Actions to Simplify Prior Authorization Process

Blue Cross and Blue Shield companies aim to improve the prior authorization process to make…

2 hours ago

MSIG USA Appoints Jayson Taylor to Lead Casualty Business

NEW YORK, June 23, 2025 /PRNewswire/ -- MSIG USA, a leading provider of specialty insurance…

2 hours ago